P. Fillatre, O. Decaux, S. Jouneau, M. Revest, A. Gacouin et al., Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients, The American Journal of Medicine, vol.127, issue.12, pp.1242-1253, 2014.
DOI : 10.1016/j.amjmed.2014.07.010

URL : https://hal.archives-ouvertes.fr/hal-01063911

H. Green, M. Paul, L. Vidal, and L. Leibovici, Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients, Pneumocystis jirovecii pneumonia in patients with or without AIDS, p.5590, 2014.

D. Cettomai, A. Gelber, and L. Christopher-stine, A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2014. (WHO Guidelines Approved by the Guidelines Review Committee). available on Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention, 792?9. 5, p.42, 2004.

A. Limper, K. Knox, G. Sarosi, N. Ampel, J. Bennett et al., An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.1, pp.96-128, 2011.
DOI : 10.1164/rccm.2008-740ST

S. Bozzette, D. Finkelstein, S. Spector, P. Frame, W. Powderly et al., A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection, New England Journal of Medicine, vol.332, issue.11, pp.693-702, 1995.
DOI : 10.1056/NEJM199503163321101

U. Overgaard and J. Helweg-larsen, Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: A retrospective study 2002???2004, Scandinavian Journal of Infectious Diseases, vol.80, issue.6-7, pp.589-95, 2007.
DOI : 10.1007/s150100070041

N. Mansharamani, D. Balachandran, I. Vernovsky, R. Garland, H. Koziel et al., Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study. Semin Arthritis Rheum Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by realtime PCR: a 4-year prospective study Pneumocystis jirovecci pneumonia in connective tissue diseases: Comparison with other immunocompromised patients, 712?20. 11. Tadros S,3370?6. 13. Teichtahl AJ, pp.86-90, 2000.

E. Bruce, L. Kearsley-fleet, K. Watson, D. Symmons, K. Hyrich et al., Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor ?: results from the British Society for Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia al. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with Bcell lymphoma receiving rituximab-containing combination chemotherapy, 1336?7. 1588?95. 16. Limper AH, pp.2043-52, 1989.

F. Lanternier, S. Cypowyj, C. Picard, J. Bustamante, O. Lortholary et al., Primary immunodeficiencies underlying fungal infections, Current Opinion in Pediatrics, vol.25, issue.6, pp.736-783, 2013.
DOI : 10.1097/MOP.0000000000000031

U. Baschant, N. Lane, and J. Tuckermann, The multiple facets of glucocorticoid action in rheumatoid arthritis, 645?55. Supplementary method Specimen processing and analysis, 2012.
DOI : 10.1210/en.2010-0456

L. Pneumocystis and . Kit, TIB MOLBIOL) according to the manufacturer's instructions. The target gene was a multi-copy gene coding for Major Surface Glycoprotein

L. Musto, M. Flanigan, and A. Eldabawi, Ten-minute silverstain for P. carinii and fungi in tissue sections, Arch Pathol Lab Med, vol.106, pp.292-94, 1982.

B. 1. Bienvenu, A. Traore, K. Plekhanova, I. Bouchrik, M. Bossard et al., Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients, International Journal of Infectious Diseases, vol.46, pp.11-18, 2016.
DOI : 10.1016/j.ijid.2016.03.018

W. Hughes, S. Kuhn, S. Chaudhary, S. Feldman, M. Verzosa et al., Successful chemoprophylaxis for Pneumocystis carinii pneumonitis Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients, 1419?26. 3. Stern A, p.5590, 1977.

H. Masur, J. Brooks, C. Benson, K. Holmes, A. Pau et al., Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.58, issue.9, pp.1308-1319, 2014.
DOI : 10.1093/cid/ciu094

J. Chapman, The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation. 27 mars, pp.644-649, 2010.

J. Maertens, S. Cesaro, G. Maschmeyer, H. Einsele, J. Donnelly et al., pneumonia in patients with haematological malignancies and stem cell transplant recipients, Journal of Antimicrobial Chemotherapy, vol.71, issue.9, pp.2397-404, 2016.
DOI : 10.1093/jac/dkw157

URL : https://hal.archives-ouvertes.fr/pasteur-01405216

N. Mansharamani, D. Balachandran, I. Vernovsky, R. Garland, and H. Koziel, Peripheral Blood CD4 + T-Lymphocyte Counts During Pneumocystis carinii Pneumonia in Immunocompromised Patients Without HIV Infection, Chest, vol.118, issue.3, pp.712-732, 2000.
DOI : 10.1378/chest.118.3.712

J. Edman, J. Kovacs, H. Masur, D. Santi, H. Elwood et al., Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi, Nature, vol.334, issue.6182, pp.519-541, 1988.
DOI : 10.1038/334519a0

T. Joffrion and M. Cushion, Sterol biosynthesis and sterol uptake in the fungal pathogen Pneumocystis carinii, FEMS Microbiology Letters, vol.311, issue.1, pp.1-9, 2010.
DOI : 10.1111/j.1574-6968.2010.02007.x

F. Gigliotti, A. Harmsen, C. Haidaris, P. Haidaris, A. Wakefield et al., Pneumocystis carinii is not universally transmissible between mammalian species, Infect Immun. juill Genetics, metabolism and host specificity of Pneumocystis carinii. Med Mycol, vol.6136, issue.11 1, pp.183-93, 1993.

O. Jirovec, Pneumocystis carinii, as the agent pf interstitial plasma cell pneumonia in man, Bol Inst Pueric. avr, vol.21, pp.5-16, 1964.

F. Gigliotti, Pneumocystis carinii Nomenclature: Response to Cushion and Stringer, Clinical Infectious Diseases, vol.42, issue.8, pp.1208-1217, 2006.
DOI : 10.1086/503041

F. Gigliotti, A. Limper, and W. T. Pneumocystis, Cold Spring Harb Perspect Med

M. , C. M. Demanche, C. Aliouat, E. Viscogliosi, E. Guillot et al., Pneumocystis species, co-evolution and pathogenic power Quantitation of absolute Pneumocystis carinii nuclear DNA content. Trophic and cystic forms isolated from infected rat lungs are haploid organisms, 233?9. 17. Thomas CF, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia, pp.708-734, 1998.

J. Vanek and O. Jirovec, [Parasitic pneumonia Interstitial plasma cell pneumonia of premature, caused by pneumocystis Carinii]. Zentralblatt Bakteriol Parasitenkd Infekt Hyg Zweite Naturwissenschaftliche Abt Allg Landwirtsch Tech Mikrobiol. 12 mai 1952 Pneumocystis pneumonia--Los, 1?2):120?7. 19. Centers for Disease Control and Prevention (CDC)

C. Ponce, M. Gallo, R. Bustamante, and S. Vargas, Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population, Clin Infect Dis Off Publ Infect Dis Soc Am. 1 févr, vol.50, issue.21, 2010.

A. Morris, K. Wei, K. Afshar, and L. Huang, Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome Epidemiology and clinical significance of pneumocystis colonization, Rheumatol Oxf Engl. mars J Infect Dis. 1 janv, vol.50197, issue.231, pp.10-17, 2008.

S. Valade, E. Azoulay, C. Damiani, F. Derouin, A. Totet et al., Pneumocystis jirovecii airborne transmission between critically ill patients and health care workers Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children):35?41. 26 Multi-locus genotype switching in Pneumocystis carinii sp. f. hominis: evidence for reinfection Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients, 1716?8. 25. Pifer LL1?8. 28. Gianella S, pp.1-10, 1978.

E. Fréalle, S. Valade, N. Guigue, S. Hamane, M. Chabé et al., colonization: frequency and putative risk factors: Table 1., Medical Mycology, vol.30, 2016.
DOI : 10.1093/mmy/myw113

P. Pneumocystis, E. Carmona, A. Limper, A. Azuma, A. Kohno et al., Update on the diagnosis and treatment of Pneumocystis pneumonia Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection, 107?38. 31, pp.126-157, 2010.

J. Kanne, D. Yandow, and C. Meyer, Pneumonia: High-Resolution CT Findings in Patients With and Without HIV Infection, American Journal of Roentgenology, vol.198, issue.6, pp.555-561, 2012.
DOI : 10.2214/AJR.11.7329

X. Mu, P. Jia, L. Gao, L. Su, C. Zhang et al., Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients, Chinese Medical Journal, vol.129, issue.17, pp.2020-2025, 2016.
DOI : 10.4103/0366-6999.189068

N. Pierre-louis and B. Dlugos, A rare cause of cavitary lung lesions CT findings in immunocompromised patients with pulmonary infections, 28?31. 36. Demirkazik FB, Akin A, pp.75-82, 2008.

Y. Zhou, J. Shetty, and M. Pins, Small-Intestine Pneumocystis jiroveci Pseudotumor as an Acquired Immunodeficiency Syndrome???Presenting Illness: Report of a Case and Review of the Literature, Archives of Pathology & Laboratory Medicine, vol.136, issue.9, pp.1001-1004, 2012.
DOI : 10.5858/arpa.2011-0221-CR

A. Zavascki and A. Maia, Pneumocystis jiroveci thyroiditis: report of 15 cases in the literature, 443?6. 39. Roux, 2007.
DOI : 10.1159/000333757

P. Fillatre, S. Chevrier, M. Revest, A. Gacouin, S. Jouneau et al., Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia, European Journal of Clinical Microbiology & Infectious Diseases, vol.362, issue.9395, pp.189-94, 2013.
DOI : 10.1016/S0140-6736(03)14740-X

URL : https://hal.archives-ouvertes.fr/inserm-00872789

S. Arend, F. Kroon, J. Van-'t-wout, J. Zahar, R. M. Azoulay et al., An analysis of 78 cases Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study Clin Infect Dis Off Publ Infect Dis Soc Am. 15 oct Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China, Pneumocystis carinii pneumonia in patients without AIDS Limper AH, pp.2436-2477, 1980.

P. Flori, B. Bellete, F. Durand, H. Raberin, C. Cazorla et al., Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens Utility of bronchoalveolar lavage in diagnosing respiratory tract infections in patients with hematological malignancies: are invasive diagnostics still needed? Ups, J Med Microbiol. juill J Med Sci. mars, vol.53122, issue.1, pp.56-60, 2004.

M. Sato, S. Ito, M. Ogura, K. Kamei, I. Miyairi et al., Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome, Pediatric Nephrology, vol.118, issue.11, pp.145-154, 2013.
DOI : 10.1378/chest.118.3.704

E. Azoulay, A. Bergeron, S. Chevret, N. Bele, B. Schlemmer et al., Polymerase Chain Reaction for Diagnosing Pneumocystis Pneumonia in Non-HIV Immunocompromised Patients With Pulmonary Infiltrates, 655?61. 52. Alanio A, Hauser PM, 2009.
DOI : 10.1378/chest.08-1309

URL : https://hal.archives-ouvertes.fr/inserm-00448960

G. Procop, S. Haddad, J. Quinn, M. Wilson, N. Henshaw et al., ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods, J Antimicrob Chemother. sept J Clin Microbiol. juill, vol.7142, issue.97, pp.2386-96, 2004.

S. Kobayashi, K. Yagi, and T. Asami, Accuracy of ?-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a metaanalysis, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. janv, vol.19, issue.11, 2013.

D. Assay-for-discrimination-between-pneumocystis-jirovecii-pneumonia, C. Infect-chemother-off, J. Wakefield, A. Pixley, F. Banerji et al., Detection of Pneumocystis carinii with DNA amplification PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups V, Dei-Cas E. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: assessing risk with blood CD4+ T cell counts al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia, 451?3. 571461?7. 59):1331?2. 60. Larsen HH, pp.678-81, 1990.

D. Zonios, J. Falloon, J. Bennett, P. Shaw, D. Chaitt et al., Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors Idiopathic CD4+ T-lymphocytopenia--four patients with opportunistic infections and no evidence of HIV infection Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia The Xlinked hyper-IgM syndrome: clinical and immunologic features of 79 patients, Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients):287?94. 63373?84. 66. Picard C, Casanova J-L, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or I?B? deficiency, pp.716-723, 1993.

L. Schimke, N. Rieber, S. Rylaarsdam, O. Cabral-marques, N. Hubbard et al., A Novel Gain-of-Function IKBA Mutation Underlies Ectodermal Dysplasia with Immunodeficiency and Polyendocrinopathy, Journal of Clinical Immunology, vol.122, issue.Suppl 2, pp.1088-99, 2013.
DOI : 10.1016/j.jaci.2008.08.026

Y. Su, J. Lu, C. Perng, and F. Chang, Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection):478?82. 69. Picard C, Fischer A. Hematopoietic stem cell transplantation and other management strategies for MHC class II deficiency, J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. déc Immunol Allergy Clin North Am. mai, vol.4130, issue.62, pp.173-181, 2008.

K. Imai, T. Morio, Y. Zhu, Y. Jin, S. Itoh et al., Clinical course of patients with WASP gene mutations The role of alveolar macrophages in Pneumocystis carinii elimination from the lower respiratory tract, 456?64. 71. Limper AH, Standing, pp.12-72, 1996.

J. Fleury, E. Escudier, M. Pocholle, C. Carre, and J. Bernaudin, Cell population obtained by bronchoalveolar lavage in Pneumocystis carinii pneumonitis, Acta Cytol. oct, vol.29, issue.5, pp.721-727, 1985.

G. Majai, E. Kiss, T. Tarr, G. Zahuczky, Z. Hartman et al., Decreased apoptophagocytic gene expression in the macrophages of systemic lupus erythematosus patients, 133?45. 74. Ezekowitz RA, 2014.

C. Steele, L. Marrero, S. Swain, A. Harmsen, M. Zheng et al., Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappaB activation Pneumocystis-mediated IL-8 release by macrophages requires coexpression of mannose receptors and TLR2 Scavenger receptor A dampens induction of inflammation in response to the fungal pathogen Pneumocystis carinii, ):1677?88. 76. Lebron F,205?11. 78. Hollifield M):3999?4005. 79. Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia, 2003.

B. Jensen, I. Lisse, J. Gerstoft, S. Borgeskov, P. Skinhøj et al., Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms, AIDS, vol.5, issue.5, 1991.
DOI : 10.1097/00002030-199105000-00008

B. Garvy and M. Qureshi, Pneumocystis cell wall beta-glucans induce dendritic cell costimulatory molecule expression and inflammatory activation through a Fas-Fas ligand mechanism Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment, J Immunol Baltim Md J Immunol Baltim Md, vol.177165, issue.8411, pp.6480-6486, 1950.

J. Phair, A. Muñoz, R. Detels, R. Kaslow, C. Rinaldo et al., The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection T cell costimulatory molecule function determines susceptibility to infection with Pneumocystis carinii in mice The host response of CD28-deficient mice to Pneumocystis infection, 3055?61. 881969?77. 89. Rose CM,23?8. 90. Zwar TD, van Driel IR, Gleeson PA. Guarding the immune system: suppression of autoimmunity by CD4+CD25+ immunoregulatory T cells, pp.161-5487, 1950.

S. Hori, T. Carvalho, and J. Demengeot, CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice, European Journal of Immunology, vol.32, issue.5, pp.1282-91, 2002.
DOI : 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#

L. Mckinley, A. Logar, F. Mcallister, M. Zheng, C. Steele et al., Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia Immunemediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia, J Immunol Baltim Md J Clin Invest. nov, vol.177104, issue.99, pp.1307-1324, 1950.

F. Gigliotti, E. Crow, S. Bhagwat, T. Wright, T. Wright et al., Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia IFN-gamma and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor, 6310?6. 952511?21. 96. Kolls JK, pp.7450-7457, 1950.

M. Kelly and J. Shellito, immunology, Future Microbiology, vol.77, issue.1, pp.43-65, 2010.
DOI : 10.1128/IAI.01208-08

M. Opata, M. Hollifield, F. Lund, T. Randall, R. Dunn et al., Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice, J Immunol Baltim Md, vol.195, issue.2, pp.611-631, 1950.

F. Lund, M. Hollifield, K. Schuer, J. Lines, T. Randall et al., B Cells Are Required for Generation of Protective Effector and Memory CD4 Cells in Response to Pneumocystis Lung Infection, The Journal of Immunology, vol.176, issue.10, pp.6147-54, 1950.
DOI : 10.4049/jimmunol.176.10.6147

W. Elsegeiny, T. Eddens, K. Chen, and J. Kolls, Anti-CD20 Antibody Therapy and Susceptibility to Pneumocystis Pneumonia, Infection and Immunity, vol.83, issue.5, pp.2043-52, 2015.
DOI : 10.1128/IAI.03099-14

P. Walzer and M. Rutledge, Humoral immunity in experimental Pneumocystis carinii infection. I. Serum and bronchial lavage fluid antibody responses in rats, J Lab Clin Med. juin, vol.97, issue.6, pp.820-853, 1981.

J. Wells, C. Haidaris, T. Wright, and F. Gigliotti, Complement and Fc Function Are Required for Optimal Antibody Prophylaxis against Pneumocystis carinii Pneumonia, Infection and Immunity, vol.74, issue.1, pp.390-393, 2006.
DOI : 10.1128/IAI.74.1.390-393.2006

F. Gigliotti and W. Hughes, Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models., Journal of Clinical Investigation, vol.81, issue.6
DOI : 10.1172/JCI113503

F. Gigliotti, C. Haidaris, T. Wright, and A. Harmsen, Passive Intranasal Monoclonal Antibody Prophylaxis against Murine Pneumocystis carinii Pneumonia, Infection and Immunity, vol.70, issue.3, pp.1069-74, 2002.
DOI : 10.1128/IAI.70.3.1069-1074.2002

J. Roths and C. Sidman, Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice, Infect Immun. mai, vol.61, issue.5, pp.1641-1650, 1993.

A. Harmsen, W. Chen, and F. Gigliotti, Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice, Infect Immun. juill, vol.63, issue.7, pp.2391-2396, 1995.

M. Zheng, J. Shellito, L. Marrero, Q. Zhong, S. Julian et al., CD4+ T cell???independent vaccination against Pneumocystis carinii in mice, Journal of Clinical Investigation, vol.108, issue.10, pp.1469-74, 2001.
DOI : 10.1172/JCI13826

H. Kling and K. Norris, Coinfection, Journal of Infectious Diseases, vol.213, issue.10, pp.1586-95, 2016.
DOI : 10.1093/infdis/jiw032

A. Lymphopenia, A double-edged sword [Internet]. [cité 5 mars 2017]. Disponible sur

R. Baccala and A. Theofilopoulos, The new paradigm of T-cell homeostatic proliferation-induced autoimmunity, Trends in Immunology, vol.26, issue.1, pp.5-8, 2005.
DOI : 10.1016/j.it.2004.11.006

L. Carli, C. Tani, S. Vagnani, V. Signorini, and M. Mosca, Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact???A systematic literature review, Seminars in Arthritis and Rheumatism, vol.45, issue.2, pp.190-194, 2015.
DOI : 10.1016/j.semarthrit.2015.05.009

M. Petri, A. Orbai, G. Alarcón, C. Gordon, J. Merrill et al., Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis & Rheumatism, vol.65, issue.Suppl, pp.2677-86, 2012.
DOI : 10.1111/j.1523-1755.2004.00443.x

M. Martin, A. Guffroy, X. Argemi, and T. Martin, Systemic lupus erythematosus and lymphopenia: Clinical and pathophysiological features], Rev Med Interne. 14 févr, 2017.

C. Li, R. Mu, X. Lu, J. He, R. Jia et al., Antilymphocyte Antibodies in Systemic Lupus Erythematosus: Association with Disease Activity and Lymphopenia, Journal of Immunology Research, vol.99, issue.2, p.672126, 2014.
DOI : 10.1177/0961203306071916

D. Symmons, M. Farr, M. Salmon, and P. Bacon, Lymphopenia in rheumatoid arthritis, J R Soc Med. août, vol.82, issue.8, pp.462-465, 1989.

M. Viguier, S. Fouéré, P. De-la-salmonière, C. Rabian, C. Lebbe et al., Peripheral Blood Lymphocyte Subset Counts in Patients with Dermatomyositis, Medicine, vol.82, issue.2, pp.82-88, 2003.
DOI : 10.1097/00005792-200303000-00002

W. Behan, P. Behan, H. Micklem, and W. Durward, Abnormalities of lymphocyte subsets in polymyositis., BMJ, vol.287, issue.6386, pp.181-183, 1983.
DOI : 10.1136/bmj.287.6386.181

H. Izzedine, P. Cacoub, V. Launay-vacher, C. Bagnis, and G. Deray, Lymphopenia in Wegener???s Granulomatosis, Nephron, vol.92, issue.2, pp.466-71, 2002.
DOI : 10.1159/000063303

M. Miyara, Z. Amoura, C. Parizot, C. Badoual, K. Dorgham et al., The immune paradox of sarcoidosis and regulatory T cells, The Journal of Experimental Medicine, vol.83, issue.2, pp.359-70, 2006.
DOI : 10.1164/ajrccm.160.5.9904045

B. Hudspith, K. Flint, D. Geraint-james, J. Brostoff, and N. Johnson, Lack of immune deficiency in sarcoidosis: compartmentalisation of the immune response., Thorax, vol.42, issue.4, pp.250-255, 1987.
DOI : 10.1136/thx.42.4.250

B. Desrues, P. Delaval, N. Genetet, C. Pencole, G. Merdrignac et al., Does peripheral blood T-lymphocyte population distribution in sarcoidosis provide a prognostic clue? Sarcoidosis, sept, vol.8, issue.2, pp.129-162, 1991.

Y. Jamilloux, C. Bernard, O. Lortholary, S. Kerever, L. Lelièvre et al., Opportunistic infections and sarcoidosis], Rev Med Interne, 2016.

T. Heimann, K. Bolnick, and A. Aufses, Prognostic Significance of Severe Preoperative Lymphopenia in Patients with Crohn??s Disease, Annals of Surgery, vol.203, issue.2, pp.132-137, 1986.
DOI : 10.1097/00000658-198602000-00004

P. Messiaen, S. Cuyx, T. Dejagere, and J. Van-der-hilst, The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review, Transpl Infect Dis Off J Transplant Soc. 30 déc, 2016.

B. Godeau, V. Coutant-perronne, L. T. Huong, D. Guillevin, L. Magadur et al., Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases, J Rheumatol. févr, vol.21, issue.2, pp.246-51, 1994.

K. Sepkowitz, Pneumocystis carinii Pneumonia in Patients Without AIDS, Clinical Infectious Diseases, vol.17, issue.Supplement_2, pp.416-422, 1993.
DOI : 10.1093/clinids/17.Supplement_2.S416

J. Lehman and A. Kalaaji, Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions, Journal of the American Academy of Dermatology, vol.63, issue.5, pp.815-838, 2010.
DOI : 10.1016/j.jaad.2009.11.588

A. Kronbichler, D. Jayne, and G. Mayer, Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis, European Journal of Clinical Investigation, vol.9, issue.Suppl 1, pp.346-68, 2015.
DOI : 10.1038/nrrheum.2013.134

M. Ward and F. Donald, Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality, Arthritis & Rheumatism, vol.32, issue.4, pp.780-789, 1999.
DOI : 10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M

M. Rodriguez and J. Fishman, Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients, Clinical Microbiology Reviews, vol.17, issue.4, pp.770-782, 2004.
DOI : 10.1128/CMR.17.4.770-782.2004

M. Yates, R. Watts, I. Bajema, M. Cid, B. Crestani et al., ERA- EDTA recommendations for the management of ANCA-associated vasculitis, Ann Rheum Dis

O. Debouverie, F. Roy-péaud, G. Béraud, C. Blanchard-delaunay, F. Roblot et al., ??v??nements infectieux au cours des vascularites n??crosantes syst??miques??: ??tude r??trospective de 82??cas, La Revue de M??decine Interne, vol.35, issue.10, pp.636-678, 2014.
DOI : 10.1016/j.revmed.2013.11.009

M. Dalakas and R. Hohlfeld, Polymyositis and dermatomyositis, The Lancet, vol.362, issue.9388, pp.971-82, 2003.
DOI : 10.1016/S0140-6736(03)14368-1

I. Marie, J. Ménard, E. Hachulla, P. Chérin, O. Benveniste et al., Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients, Seminars in Arthritis and Rheumatism, vol.41, issue.1, pp.48-60, 2011.
DOI : 10.1016/j.semarthrit.2010.08.003

C. Berger, V. Greiff, S. John, K. Koenig, M. Bigler et al., Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study, Clin Exp Rheumatol. avr, vol.33, issue.2, pp.122-125, 2015.

S. Mori and M. Sugimoto, Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations, Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, vol.9, issue.1, pp.29-40, 2015.
DOI : 10.4137/CCRPM.S23286

S. Mori, I. Cho, and M. Sugimoto, A Cluster of Pneumocystis jirovecii Infection Among Outpatients with Rheumatoid Arthritis, The Journal of Rheumatology, vol.37, issue.7, pp.1547-1555, 2010.
DOI : 10.3899/jrheum.091294

P. Okafor, F. Farraye, A. Okafor, and D. Erim, Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn???s Disease, Digestive Diseases and Sciences, vol.44, issue.2014, pp.3743-55, 2015.
DOI : 10.1016/j.amjmed.2014.07.010

J. Gerrard, Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults, Med J Aust. 6 mars, vol.162, issue.5, pp.233-238, 1995.

S. Yale and A. Limper, Pneumocystis carinii Pneumonia in Patients Without Acquired Immunodeficiency Syndrome: Associated Illnesses and Prior Corticosteroid Therapy, Mayo Clinic Proceedings, vol.71, issue.1, pp.5-13, 1996.
DOI : 10.4065/71.1.5

H. Bachelez, B. Schremmer, J. Cadranel, F. Mouly, C. Sarfati et al., Fulminant Pneumocystis carinii Pneumonia in 4 Patients With Dermatomyositis, Archives of Internal Medicine, vol.157, issue.13, pp.1501-1504, 1997.
DOI : 10.1001/archinte.1997.00440340145015

B. Godeau, J. Mainardi, E. Hachulla, L. Guillevin, F. Roudot-thoraval et al., Le risque de pneumocystose est-il pr??visible au cours de la maladie de Wegener?, La Revue de M??decine Interne, vol.14, issue.10, p.1025, 1993.
DOI : 10.1016/S0248-8663(05)80142-0

D. Gupta, A. Zachariah, H. Roppelt, A. Patel, and B. Gruber, Prophylactic Antibiotic Usage for Pneumocystis jirovecii Pneumonia in Patients With Systemic Lupus Erythematosus on Cyclophosphamide, JCR: Journal of Clinical Rheumatology, vol.14, issue.5, pp.267-72, 2008.
DOI : 10.1097/RHU.0b013e31817a7e30

A. Stenger, P. Houtman, G. Bruyn, H. Eggink, and H. Pasma, Pneumocystis Carinii Pneumonia Associated with Low Dose Methotrexate Treatment for Rheumatoid Arthritis, Scandinavian Journal of Rheumatology, vol.18, issue.1, pp.51-54, 1994.
DOI : 10.1093/rheumatology/31.1.71

N. Roux, R. Flipo, B. Cortet, J. Lafitte, A. Tonnel et al., Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases, Rev Rhum Engl Ed. juin, vol.63, issue.6, pp.453-459, 1996.

S. Krebs and R. Gibbons, Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia, Mil Med. janv, vol.161, issue.1, pp.58-60, 1996.

J. Ocampo, Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab, J Crohns Colitis. mai, vol.6, issue.4, pp.483-490, 2012.

J. Lee, D. Bell, R. Guinness, and T. Ahmad, Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNF?? naive patient with ulcerative colitis, World Journal of Gastroenterology, vol.15, issue.15, pp.1897-900, 2009.
DOI : 10.3748/wjg.15.1897

S. Itaba, T. Iwasa, Y. Sadamoto, T. Nasu, T. Misawa et al., Pneumocystis Pneumonia During Combined Therapy of Infliximab, Corticosteroid, and Azathioprine in a Patient with Crohn???s Disease, Digestive Diseases and Sciences, vol.113, issue.6, pp.1438-1479, 2007.
DOI : 10.7326/0003-4819-123-2-199507150-00009

Y. Zhang and Y. Zheng, Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases, Rheumatology International, vol.41, issue.3, pp.1765-71, 2014.
DOI : 10.1016/j.semarthrit.2011.05.004

S. Vallabhaneni and T. Chiller, Fungal Infections and New Biologic Therapies, Current Rheumatology Reports, vol.64, issue.12, p.29, 2016.
DOI : 10.1002/acr.21784

J. Grubbs and J. Baddley, Pneumocystis jirovecii Pneumonia in Patients Receiving Tumor-Necrosis-Factor-Inhibitor Therapy: Implications for Chemoprophylaxis, Current Rheumatology Reports, vol.64, issue.10, p.445, 2014.
DOI : 10.1002/acr.21805

N. Kaur and T. Mahl, Pneumocystis jiroveci (carinii) Pneumonia After Infliximab Therapy: A Review of 84 Cases, Digestive Diseases and Sciences, vol.126, issue.6, pp.1481-1485, 2007.
DOI : 10.1007/s10620-006-9250-x

J. Barreto, L. Ice, C. Thompson, P. Tosh, D. Osmon et al., Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy, American Journal of Hematology, vol.35, issue.11, pp.1113-1120, 2016.
DOI : 10.1128/AAC.35.9.1884

F. Roblot and P. Roblot, Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases], Rev Med Interne. mars, vol.38, issue.3, pp.160-166, 2017.

Q. Reynaud, I. Durieu, M. Dutertre, S. Ledochowski, S. Durupt et al., Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies, Autoimmunity Reviews, vol.14, issue.4, pp.304-317, 2015.
DOI : 10.1016/j.autrev.2014.11.014

D. Cettomai, A. Gelber, and L. Christopher-stine, A Survey of Rheumatologists' Practice for Prescribing Pneumocystis Prophylaxis, The Journal of Rheumatology, vol.37, issue.4, pp.792-801, 2010.
DOI : 10.3899/jrheum.090843

H. Green, M. Paul, L. Vidal, and L. Leibovici, Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non-HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials, Mayo Clinic Proceedings, vol.82, issue.9, pp.1052-1061, 2007.
DOI : 10.4065/82.9.1052

A. Limper, K. Knox, G. Sarosi, N. Ampel, J. Bennett et al., An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.1, pp.96-128, 2011.
DOI : 10.1164/rccm.2008-740ST

L. Cooley, C. Dendle, J. Wolf, B. Teh, S. Chen et al., pneumonia in patients with haematological and solid malignancies, 2014, Internal Medicine Journal, vol.57, issue.3, pp.1350-63, 2014.
DOI : 10.1093/cid/cit413

S. Tadros, A. Teichtahl, S. Ciciriello, and I. Wicks, Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case???control study, Seminars in Arthritis and Rheumatism, vol.46, issue.6, 2016.
DOI : 10.1016/j.semarthrit.2016.09.009

A. Warnock and D. Rimland, Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia, Pharmacotherapy. déc, vol.16, issue.6, pp.1030-1038, 1996.

M. Kimura, S. Tanaka, A. Ishikawa, H. Endo, S. Hirohata et al., Comparison of trimethoprim???sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease, Rheumatology International, vol.3, issue.7, pp.673-679, 2008.
DOI : 10.11150/kansenshogakuzasshi1970.73.1123

C. Stegeman, J. Tervaert, P. De-jong, and C. Kallenberg, Trimethoprim???Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's Granulomatosis, New England Journal of Medicine, vol.335, issue.1, pp.16-20, 1996.
DOI : 10.1056/NEJM199607043350103

J. Pope, D. Jerome, D. Fenlon, A. Krizova, and J. Ouimet, Frequency of adverse drug reactions in patients with systemic lupus erythematosus, J Rheumatol. mars, vol.30, issue.3, pp.480-484, 2003.

R. Maezawa, K. Kurasawa, S. Arai, H. Okada, T. Owada et al., pneumonia, in patients with connective tissue diseases, Modern Rheumatology, vol.327, issue.1, pp.62-70, 2013.
DOI : 10.1007/s00296-007-0505-4

K. Takenaka, Y. Komiya, M. Ota, H. Yamazaki, and K. Nagasaka, A dose-escalation regimen of trimethoprim???sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases, Modern Rheumatology, vol.15, issue.4, pp.752-760, 2013.
DOI : 10.1177/0961203307086640

J. Ioannidis, J. Cappelleri, P. Skolnik, J. Lau, and H. Sacks, A Meta-analysis of the Relative Efficacy and Toxicity of Pneumocystis carinii Prophylactic Regimens, Archives of Internal Medicine, vol.156, issue.2, pp.177-88, 1996.
DOI : 10.1001/archinte.1996.00440020081010

H. Groenendal and F. Rampen, Methotrexate and trimethoprim-sulphamethoxazole-a potentially hazardous combination, Clinical and Experimental Dermatology, vol.26, issue.5, pp.358-60, 1990.
DOI : 10.1001/archinte.145.11.2035

G. Chevrel, J. Brantus, J. Sainte-laudy, and P. Miossec, Allergic pancytopenia to trimethoprim-sulphamethoxazole for Pneumocystis carinii pneumonia following methotrexate treatment for rheumatoid arthritis., Rheumatology, vol.38, issue.5, pp.475-481, 1999.
DOI : 10.1093/rheumatology/38.5.475

C. Thomas and A. Limper, Pneumocystis Pneumonia, New England Journal of Medicine, vol.350, issue.24, pp.2487-98, 2004.
DOI : 10.1056/NEJMra032588

N. Iikuni, M. Kitahama, S. Ohta, H. Okamoto, N. Kamatani et al., pneumonia infection risk factors in patients with connective tissue disease, Modern Rheumatology, vol.345, issue.5, pp.282-290, 2006.
DOI : 10.1165/ajrcmb.16.2.9032117

M. Khellaf and B. Godeau, Pneumocystis pneumonia among patients with systemic diseases]. Presse Medicale Paris Fr 1983, févr, vol.38, issue.2, pp.251-260, 2009.